Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Timothy E. Hoen"'
Publikováno v:
Biomaterials. 34:6922-6929
Mucosal epithelia use osmotic gradients for fluid absorption and secretion. We hypothesized that administration of hypotonic solutions would induce fluid uptake that could be advantageous for rapidly delivering drugs through mucus to the vaginal epit
Autor:
Qi Yang, Kenetta L. Nunn, Steve R. Roffler, Timothy E. Hoen, Ying Ying Wang, Richard A. Cone, Justin D. McCallen, Samuel K. Lai, Sumon Chattopadhyay, Christine E. Henry, Holly A. Schroeder, Laura M. Ensign, Thomas R. Moench, Thuy Hoang
Publikováno v:
Acta biomaterialia. 43
Antibodies that specifically bind polyethylene glycol (PEG) can lead to rapid elimination of PEGylated therapeutics from the systemic circulation. We have recently shown that virus-binding IgG can immobilize viruses in mucus via multiple low-affinity
Publikováno v:
Contraception. 58:51-60
Development of new vaginal products, such as microbiocides and contraceptives, requires in vivo testing of their effect on fertility. Rabbits, unlike smaller laboratory animals such as rats and mice, which inseminate in the uterus, inseminate vaginal
Publikováno v:
Biology of Reproduction. 56:153-159
Immune infertility in humans correlates clinically with the presence of anti-sperm antibodies that trap (agglutinate) sperm in semen and cervical mucus. To test whether sperm-agglutinating antibodies can be effective contraceptive agents, several mou
Autor:
Terence A. Tse, Benjamin C. Tang, Timothy E. Hoen, Laura M. Ensign, Ying Ying Wang, Richard A. Cone, Justin Hanes
Publikováno v:
Science Translational Medicine. 4
Incomplete coverage and short duration of action limit the effectiveness of vaginally administered drugs, including microbicides for preventing sexually transmitted infections. We investigated vaginal distribution, retention, and safety of nanopartic
Publikováno v:
BMC Infectious Diseases, Vol 10, Iss 1, p 331 (2010)
BMC Infectious Diseases
BMC Infectious Diseases
Background Several active ingredients proposed as vaginal microbicides have been shown paradoxically to increase susceptibility to infection in mouse genital herpes (HSV-2) vaginal susceptibility models and in clinical trials. In addition, "inactive
Publikováno v:
Journal of Infectious Diseases. 169:647-649
Vaginal application of human herpes simplex virus (HSV) antiserum, complement-inactivated antiserum, or IgG purified from antiserum protected mice (P < .001, P < .001, and P < .01, respectively) from visible signs of genital HSV-2 infection after sub
Autor:
Kristen V. Khanna, Kevin J. Whaley, Larry Zeitlin, Thomas R. Moench, Karim Mehrazar, Richard A. Cone, Zhaohao Liao, James E.K. Hildreth, Timothy E. Hoen, Leonard Shultz, Richard B. Markham
Because both HIV-1 virions and HIV-infected cells are present in the semen and cervical mucus of infected individuals, HIV-1 prevention strategies must consider both cell-free and cell-associated virus. Antibodies that target HIV-1 virions have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f260d8191ac18a1018fd1319a94cefe
https://europepmc.org/articles/PMC150835/
https://europepmc.org/articles/PMC150835/
Autor:
Stuart S. Olmsted, John W. Kreider, Sharon L. Achilles, Larry Zeitlin, Thomas R. Moench, Timothy E. Hoen, Ann E. Jerse, Kevin J. Whaley, Richard A. Cone, Tracy A. Hegarty
Publikováno v:
Sexually transmitted diseases. 28(7)
BufferGel is a novel spermicidal and microbicidal gel formulated to maintain the natural protective acidity of the vagina by acidifying semen, which otherwise alkalinizes the vagina.To test the efficacy of BufferGel for preventing sexually transmitte
Publikováno v:
The Journal of infectious diseases. 168(4)
A vaginal application of a commercially available contraceptive jelly containing nonoxynol-9 (N9) prevented vaginal transmission of herpes simplex virus type 2 (HSV-2) infections in the mouse. When N9 jelly was delivered to the vagina with the virus